Effect of recombinant human erythropoietin in preterm infants

Twenty‐five premature infants (mean gestational age±SD, 31.4±1.9 weeks) were administered subcutaneously recombinant human erythropoietin (rHuEpo) at a dose of 300 u/kg of body weight three times a week beginning on the third day of life and continuing for 6 weeks. The controls (n=23) were premature...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of haematology 1999-08, Vol.63 (2), p.71-76
Hauptverfasser:	Krallis, Nikolaos, Cholevas, Vasilis, Mavridis, Anestis, Georgiou, Ioannis, Bourantas, Konstantinos, Andronikou, Styliani
Format:	Artikel
Sprache:	eng
Schlagworte:	2,3-Diphosphoglycerate - blood Adenosine Triphosphate - blood Anemia - drug therapy Anemia - prevention & control Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Energy Metabolism Erythrocytes - metabolism Erythropoietin - blood Erythropoietin - therapeutic use Follow-Up Studies Gestational Age Humans Infant, Newborn Infant, Premature Medical sciences Pharmacology. Drug treatments Phosphates - blood Prospective Studies Receptors, Transferrin - blood Recombinant Proteins red blood cell organic Pi compounds rHuEpo sTfR Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!